1751 RIVER RUN, FORT WORTH, TX
Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Announces Key Appointment of Industry Veteran to Board of Directors
Annual Report to Security Holders
Actuate Therapeutics Shows Positive Phase 2 Results for Elraglusib in Pancreatic Cancer at ASCO GI 2026
Actuate Therapeutics Enters $100 Million At The Market Issuance Agreement
Other Events
Announces Pricing of $15.0 Million Public Offering of Common Stock
News, Securities Holder Rights or Indentures, Material Contracts
Q1
FY 2025
Q3
FY 2024
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities